iLof
Generated by Meeveem AI
"Accelerating personalised medicine through AI-powered optical biomarker discovery"
About iLof
iLoF develops Optomics, a platform combining photonics and AI to turn small blood samples into optical fingerprints for personalised medicine. Its work spans clinical trial stratification, diagnostics research and drug development, including Alzheimer's disease, lung cancer and ovarian cancer. The company reports up to 40% lower screening costs and 70% shorter recruitment time in its Alzheimer's trial pathway.
Founded in 2019, iLoF has offices in London, Porto and New York. Its biomarker library draws on research across more than 50 clinical sites in nine countries. Physical measurement takes under 30 seconds; selected CE-marked device components are designated for research use only.
Multidisciplinary development
The team brings together software and hardware engineering, product development, data science, clinical biology and operations. Its platform connects laboratory instrument development with clinical research and pharmaceutical applications.
Research partnerships
iLoF’s development milestones include an Alzheimer’s clinical pilot supported by Roche and participation in the Bio-Hermes-002 study supported by the Global Alzheimer’s Platform Foundation.
22
Team Members
2019
Founded
Diagnostics
Sector
Hybrid
Work Environment